Mithra Signs LSA for Commercialization of Tibelia® in Liechtenstein and Switzerland

  • Mithra grants license to Spirig Healthcare (Stada Group) for commercialization of its hormone treatment Tibelia® in Liechtenstein and Switzerland
  • Tibelia® is currently marketed in about 30 countries through existing license and supply agreements

Liege, Belgium, 11 June 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces it has entered into a license and supply agreement with Spirig Healthcare AG for the commercialization of its tibolone-based product Tibelia® in Liechtenstein and Switzerland.